These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38440737)

  • 21. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome.
    Pengo V; Ruffatti A; Legnani C; Gresele P; Barcellona D; Erba N; Testa S; Marongiu F; Bison E; Denas G; Banzato A; Padayattil Jose S; Iliceto S
    J Thromb Haemost; 2010 Feb; 8(2):237-42. PubMed ID: 19874470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypes in antiphospholipid syndrome: A hierarchical cluster analysis based on two independent databases.
    Taieb D; Moyon Q; Lhote R; Annesi-Maesano I; Haroche J; Cervera R; Amoura Z; Cohen Aubart F
    J Autoimmun; 2024 Apr; 144():103173. PubMed ID: 38330544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus.
    Urrego-Callejas T; Hernández A; Ruiz Giraldo S; Frade-Sosa B; Vanegas-García AL; Muñoz CH; Rua C; Duque Botero J; González LA; Vásquez G; Gómez-Puerta JA
    Reumatol Clin (Engl Ed); 2023 Apr; 19(4):197-203. PubMed ID: 37061281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome.
    Del Ross T; Ruffatti A; Cuffaro S; Tonello M; Calligaro A; Favaro M; Facchinetti M; Hoxha A; Punzi L
    Thromb Res; 2015 Nov; 136(5):883-6. PubMed ID: 26410418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.
    Chayoua W; Kelchtermans H; Moore GW; Musiał J; Wahl D; de Laat B; Devreese KMJ
    J Thromb Haemost; 2018 Oct; 16(10):2016-2023. PubMed ID: 30079628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.
    Radin M; Sciascia S; Erkan D; Pengo V; Tektonidou MG; Ugarte A; Meroni P; Ji L; Belmont HM; Cohen H; Ramires de Jesús G; Branch DW; Fortin PR; Andreoli L; Petri M; Rodriguez E; Rodriguez-Pinto I; Knight JS; Atsumi T; Willis R; Gonzalez E; Lopez-Pedrera R; Rossi Gandara AP; Borges Gualhardo Vendramini M; Banzato A; Sevim E; Barbhaiya M; Efthymiou M; Mackie I; Bertolaccini ML; Andrade D;
    Semin Arthritis Rheum; 2019 Dec; 49(3):464-468. PubMed ID: 31153708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity.
    Akyüz Dağlı P; Erden A; Babaoğlu H; Karakaş Ö; Özdemir Ulusoy B; Konak HE; Armağan B; Erten Ş; Omma A
    Ir J Med Sci; 2024 Apr; 193(2):1099-1107. PubMed ID: 37737913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic lupus erythematosus and antiphospholipid syndrome - diagnostic and therapeutic problems].
    Zdrojewski Z
    Wiad Lek; 2018; 71(1 pt 1):40-46. PubMed ID: 29558350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature.
    Franco AMM; Medina FMC; Balbi GGM; Levy RA; Signorelli F
    Lupus; 2020 Oct; 29(12):1528-1543. PubMed ID: 32814509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry").
    Erton ZB; K Leaf R; de Andrade D; Clarke AE; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Gerosa M; Fortin PR; Lopez-Pedrera C; Atsumi T; Zhang Z; Cohen H; Ramires de Jesús G; Branch DW; Wahl D; Andreoli L; Rodriguez-Almaraz E; Petri M; Barilaro G; Zuo Y; Artim-Esen B; Willis R; Quintana R; Vendramini MB; Barber MW; Bertolaccini ML; Roubey R; Erkan D
    Lupus; 2022 Dec; 31(14):1770-1776. PubMed ID: 36206383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study.
    Guédon AF; Catano J; Ricard L; Laurent C; de Moreuil C; Urbanski G; Deriaz S; Gerotziafas G; Elalamy I; Audemard A; Chasset F; Alamowitch S; Sellam J; Maillot F; Boffa JJ; Cohen A; Abisror N; Fain O; Mekinian A
    Arthritis Res Ther; 2022 Jan; 24(1):33. PubMed ID: 35078523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?
    Gómez-Puerta JA; Martín H; Amigo MC; Aguirre MA; Camps MT; Cuadrado MJ; Hughes GRV; Khamashta MA
    Medicine (Baltimore); 2005 Jul; 84(4):225-230. PubMed ID: 16010207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study.
    Ogata Y; Fujieda Y; Sugawara M; Sato T; Ohnishi N; Kono M; Kato M; Oku K; Amengual O; Atsumi T
    Rheumatology (Oxford); 2021 Mar; 60(3):1331-1337. PubMed ID: 32944779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    J Thromb Haemost; 2014 Nov; 12(11):1801-9. PubMed ID: 25196808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-criteria manifestations in the presence of antiphospholipid antibodies in a paediatric cohort.
    Morán-Álvarez P; Andreu-Suárez Á; Caballero-Mota L; Gassiot-Riu S; Berrueco-Moreno R; Calzada-Hernández J; Antón-López J; Vázquez-Díaz M; Boteanu A
    Rheumatology (Oxford); 2022 Nov; 61(11):4465-4471. PubMed ID: 35137009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistent antiphospholipid syndrome and myeloproliferative neoplasm.
    Sayar Z; Nallamilli S; Efthymiou M; Lambert J; Cohen H
    Lupus; 2021 Aug; 30(9):1502-1508. PubMed ID: 34192956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.
    Pérez D; Stojanovich L; Naranjo L; Stanisavljevic N; Bogdanovic G; Serrano M; Serrano A
    Front Immunol; 2018; 9():2644. PubMed ID: 30524428
    [No Abstract]   [Full Text] [Related]  

  • 40. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
    Balbi GGM; Ahmadzadeh Y; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Lopez-Pedrera C; Fortin PR; Wahl D; Gerosa M; de Jesús GR; Ji L; Atsumi T; Efthymiou M; Branch DW; Nalli C; Rodriguez Almaraz E; Petri M; Cervera R; Knight JS; Artim-Esen B; Willis R; Bertolaccini ML; Cohen H; Roubey R; Erkan D; de Andrade DCO;
    Rheumatology (Oxford); 2024 Mar; 63(3):772-779. PubMed ID: 37307082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.